Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures

Annals of Hematology

Volumn 94, Issue 9, 2015, Pages 1457-1461

  Kim, Ji Hyun ^a   Baek, Chung Hee ^a   Min, Ji Yeon ^a   Kim, Joon Seok ^a   Kim, Soon Bae ^a   Kim, Hyosang ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Antiplatelet agent; Desmopressin; Invasive procedure; Uremia

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CILOSTAZOL; CLOPIDOGREL; CREATININE; DESMOPRESSIN; SODIUM; ANTIDIURETIC AGENT; ANTITHROMBOCYTIC AGENT; ARGIPRESSIN[1 DEAMINO];

ADULT; ARTICLE; BRACHIAL ANGIOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; LEG ANGIOGRAPHY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS NEPHROSTOMY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SODIUM BLOOD LEVEL; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; UREMIA; AGED; BLOOD; METABOLISM; RENAL REPLACEMENT THERAPY; THROMBOCYTE;

ADULT; AGED; ANTIDIURETIC AGENTS; BLOOD PLATELETS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHROSTOMY, PERCUTANEOUS; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROSPECTIVE STUDIES; RENAL DIALYSIS; UREMIA;

EID: 84938746918     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2384-1     Document Type: Article

References (27)

1. Horl WH (2010) Other blood and immune disorders in chronic kidney disease. In: Floege J, Johnson RJ, Feehally J (eds) Comprehensive clinical nephrology, 4th edn. Elsevier, St. Louis, p 959–968
2. Remuzzi G, Galbusera M, Boccardo P (2009) Disorders on hemostasis in dialysis patients. In: Henrich WL (ed) Principles and practice of dialysis, 4th edn, p 489–498
3. Baron TH, Kamath PS, McBane RD (2013) Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 368:2113–2124. doi:10.1056/NEJMra1206531
4. Mattix H, Singh AK (1999) Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 8:715–718
5. Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB (2010) Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract 114:c248–c252
6. Francis J, Francis D, Larson L, Helms E, Garcia M (1999) Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 10:132–136. doi:10.1080/09537109976194
7. Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P (2003) Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J kidney Dis Off J Natl Kidney Found 42:746–751
8. Franchini M (2007) The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 82:731–735. doi:10.1002/ajh.20940
9. Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP (2011) Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J kidney Dis Off J Natl Kidney Found 57:850–855. doi:10.1053/j.ajkd.2010.12.019
10. Mannucci PM, Remuzzi G, Pusineri F et al (1983) Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8–12
11. Cho YU, Jang S, Park CJ, Chi HS (2008) Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci 38:247–253
12. Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30:579–589. doi:10.1055/s-2004-835678
13. Sohal AS, Gangji AS, Crowther MA, Treleaven D (2006) Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 118:417–422
14. Ho SJ, Gemmell R, Brighton TA (2008) Platelet function testing in uraemic patients. Hematology 13:49–58. doi:10.1179/102453308X315834
15. Kaw D, Malhotra D (2006) Platelet dysfunction and end-stage renal disease. Semin Dial 19:317–322
16. Koscielny J, von Tempelhoff GF, Ziemer S et al (2004) A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost Off J Int Acad Clin Appl Thromb Hemost 10:155–166
17. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M (2007) Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost JTH 5:2393–2398. doi:10.1111/j.1538-7836.2007.02752.x
18. Escolar G, Cases A, Vinas M et al (1999) Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 84:614–619
19. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G (2008) Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 99:14–26. doi:10.1160/TH07-08-0530
20. Schulman S (2012) Pharmacologic tools to reduce bleeding in surgery. Hematol Educ Prog Am Soc Hematol Am Soc Hematol Educ Prog 2012:517–521. doi:10.1182/asheducation-2012.1.517
21. Mackinnon B, Fraser E, Simpson K, Fox JG, Geddes C (2008) Is it necessary to stop antiplatelet agents before a native renal biopsy? Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 23:3566–3570. doi:10.1093/ndt/gfn282
22. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J (2010) Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg 74:279–285. doi:10.1016/j.wneu.2010.05.030
23. Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG (2007) Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth 21:851–854. doi:10.1053/j.jvca.2007.05.009
24. Leithauser B, Zielske D, Seyfert UT, Jung F (2008) Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 39:293–302
25. Reiter RA, Mayr F, Blazicek H et al (2003) Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 102:4594–4599. doi:10.1182/blood-2002-11-3566
26. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G (1986) Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414–416
27. Kaufman JS, O’Connor TZ, Zhang JH et al (2003) Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol JASN 14:2313–2321